Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Melanoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Ocular Melanoma (108
)
Uveal Melanoma (104
)
Cutaneous Melanoma (87
)
Mucosal Melanoma (32
)
Ocular Melanoma (108
)
Uveal Melanoma (104
)
Cutaneous Melanoma (87
)
Mucosal Melanoma (32
)
›
Associations
(946)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks (New B)
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3wk
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3 weeks - (New B)
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
C1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
C1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
C1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
C1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
LDH elevation
Melanoma
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
aldesleukin
Sensitive: A1 - Approval
aldesleukin
Sensitive
:
A1
aldesleukin
Sensitive: A1 - Approval
aldesleukin
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
BRAF V600 wild-type
Melanoma
BRAF V600 wild-type
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
No biomarker
Cutaneous Melanoma
TC
Sensitive: A2 - Guideline
TC
Sensitive
:
A2
TC
Sensitive: A2 - Guideline
TC
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login